Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fiege

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Anesthesiology|April 8, 2000
Malignant hyperthermia as a cause for postoperative rhabdomyolysisF Wappler, M Fiege
Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS|June 25, 2003
[Malignant hyperthermia--update 2002]M Fiege, F Wappler
Der Anaesthesist|March 3, 2007
[Key performance indicators of OR efficiency. Myths and evidence of key performance indicators in OR management]M Schuster, L L Wicha, M Fiege
Der Anaesthesist|April 12, 2011
[Further education in anesthesiology. Implementation at the University Hospital Hamburg-Eppendorf]G N Schmidt, M Fiege, A E Goetz
British Journal of Anaesthesia|August 21, 2008
Influence of resident training on anaesthesia induction timesM Schuster, T Kotjan, M Fiege, et al.
British Journal of Anaesthesia|March 7, 2002
Pathophysiological role of the serotonin system in malignant hyperthermiaF Wappler, M Fiege, J Schulte am Esch
Anesthesiology|January 19, 2000
Hemodynamic and metabolic alterations in response to graded exercise in a patient susceptible to malignant hyperthermiaF Wappler, M Fiege, M Antz, et al.
Der Anaesthesist|August 30, 2007
[Utilization rates and turnover times as indicators of OR workflow efficiency]M Schuster, L L Wicha, M Fiege, et al.
Der Anaesthesist|April 1, 2003
[Dantrolene. Pharmacological and therapeutic aspects]M U Gerbershagen, M Fiege, T Krause, et al.
Anaesthesia|March 17, 2004
Dantrolene--a review of its pharmacology, therapeutic use and new developmentsT Krause, M U Gerbershagen, M Fiege, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Anesthesiology|April 8, 2000
Malignant hyperthermia as a cause for postoperative rhabdomyolysisF Wappler, M Fiege
Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS|June 25, 2003
[Malignant hyperthermia--update 2002]M Fiege, F Wappler
Der Anaesthesist|March 3, 2007
[Key performance indicators of OR efficiency. Myths and evidence of key performance indicators in OR management]M Schuster, L L Wicha, M Fiege
Der Anaesthesist|April 12, 2011
[Further education in anesthesiology. Implementation at the University Hospital Hamburg-Eppendorf]G N Schmidt, M Fiege, A E Goetz
British Journal of Anaesthesia|August 21, 2008
Influence of resident training on anaesthesia induction timesM Schuster, T Kotjan, M Fiege, et al.
British Journal of Anaesthesia|March 7, 2002
Pathophysiological role of the serotonin system in malignant hyperthermiaF Wappler, M Fiege, J Schulte am Esch
Anesthesiology|January 19, 2000
Hemodynamic and metabolic alterations in response to graded exercise in a patient susceptible to malignant hyperthermiaF Wappler, M Fiege, M Antz, et al.
Der Anaesthesist|August 30, 2007
[Utilization rates and turnover times as indicators of OR workflow efficiency]M Schuster, L L Wicha, M Fiege, et al.
Der Anaesthesist|April 1, 2003
[Dantrolene. Pharmacological and therapeutic aspects]M U Gerbershagen, M Fiege, T Krause, et al.
Anaesthesia|March 17, 2004
Dantrolene--a review of its pharmacology, therapeutic use and new developmentsT Krause, M U Gerbershagen, M Fiege, et al.
Pageof 3